Fermenta Biotech Q4 FY26: Funding a ₹110 Cr Capex With 17.4% ROE and a Plot in Thane

Section 1 — At a Glance

Fermenta Biotech has navigated a highly volatile transition, stabilizing its core operations to report a consolidated FY26 revenue of ₹525.43 Cr, a noticeable recovery from the ₹335.19 Cr low of FY24. The net profit has similarly rebounded, posting ₹71.77 Cr for the full year, a sharp contrast to the ₹23.06 Cr loss two years prior. Much of this turnaround is anchored in the human nutrition segment, particularly the sustained demand for its Vitamin D3 portfolio, which provides the baseline for the company’s 20.4% ROCE.

However, beneath the headline growth, the Q4 FY26 numbers present immediate friction. Quarterly revenue contracted by 13% YoY to ₹121.58 Cr, and net profit for the quarter shrank to ₹19.19 Cr. Management’s capital allocation strategy is aggressively shifting toward capacity expansion, underscored by the board’s approval of a ₹110 Cr capex for the Dahej facility to manufacture plant-based Vitamin D3 and enzymes across FY26–FY27. Real turnarounds are confirmed on the cash flow statement, not the P&L, and Fermenta’s operating cash flow generation of ₹92.83 Cr in FY26 provides the necessary runway for this pivot. As the company preps a ₹150 Cr fundraise to support this next phase, the spotlight shifts from survival to execution.

Section 2 — Introduction

Fermenta Biotech has been around since 1951, which in corporate years makes it ancient, and in Indian pharma years makes it a survivor. For decades, they have quietly operated as a vital cog in the global supply chain, primarily shipping active pharmaceutical ingredients (APIs) and enzymes out of their facilities in Gujarat and Himachal Pradesh.

But Fermenta is a company with a fascinating dual identity. On one hand, they are a biotechnology entity serving over 350 global customers across 60 countries. On the other, they are a company that occasionally sells prime Thane commercial real estate to shore up the balance sheet when the core business needs a breather. It is an unusual hedge, but in the notoriously cyclical world of bulk drugs, having a lucrative physical asset to monetize is a feature, not a bug.

Section 3 — Business Model: WTF Do They Even Do?

If you have ever felt vaguely guilty about not spending enough time in the sun and swallowed a dietary supplement to compensate, there is a decent chance Fermenta manufactured the active ingredient. They are a global powerhouse in Vitamin D3, extracting it from sheep wool grease (cholesterol) and shipping it worldwide.

Their revenue mix is a tale of two diets: human nutrition and animal feed. The human segment is where the margins wear a suit and tie, catering to premium pharmaceutical and dietary brands. The animal nutrition segment, however, is a high-volume, bare-knuckle brawl where pricing is dictated by the whims of global commodity cycles and whatever the Chinese manufacturers are feeling on a given Tuesday. Throw in a dash of environmental solutions (wastewater treatment) and an enzyme business, and you have a biotech company that acts like an FMCG supplier, subject to the same inventory channel gluts and demand spikes.

Does a business model heavily tethered to a single vitamin create deep expertise, or just a deeply vulnerable revenue stream when the cycle turns?

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

The top-line momentum hit a speed bump in Q4. Revenue slipped sequentially and YoY, taking the operating profit down with it. A 45% YoY drop in operating profit on a 13% revenue decline suggests negative operating leverage is kicking in. Sequential margin compression in a high-fixed-cost business is the first whisper of a pricing war, or at least a normalization of channel inventory.

Management noted the ₹110 Cr Dahej capex approval as the primary lever for the coming quarters. Expanding into plant-based Vitamin D3 is management’s bid to capture the premium vegan supplement market. It is an aggressive play,